ପାଲିଭିଜୁମାବ

ପାଲିଭିଜୁମାବ
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	RSV protein F
Clinical data
Trade names	Synagis
AHFS/Drugs.com	monograph
MedlinePlus	a698034
data	EU EMA: yes; US DailyMed: Palivizumab;
Pregnancy; category	AU: N ; US: C (Risk not ruled out) ; ;
Routes of; administration	Intramuscular
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	18-20 days
Chemical and physical data
Formula	C6470H10056N1700O2008S50
Molar mass	୧,୪୫,୩୮୮.୫୧ g·mol−1
(verify)

ପାଲିଭିଜୁମାବ, ଏକ ବିକ୍ରୟ ନାମ ସିନେଜିସ, ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହେଉଛି, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଧିକ ବିପଦ ଥିବା ଲୋକଙ୍କଠାରେ ଗମ୍ଭୀର ଶ୍ୱାସକ୍ରିୟା ସିନ୍ସିଟିଆଲ୍ ଜୀବାଣୁ (Respiratory syncytial virus/ ଆରଏସଭି) ସଂକ୍ରମଣକୁ ରୋକିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ^[୧] ଏଥିରେ ୬ ମାସରୁ କମ୍ ବୟସ୍କ ଓ ଅକାଳରେ ଜନ୍ମ ହୋଇଥିଲେ ଏବଂ ଦୁଇ ବର୍ଷରୁ କମ ବୟସର ପିଲା ହୃତ୍‌ପିଣ୍ଡ କିମ୍ବା ଫୁସଫୁସ ରୋଗରେ ଆକ୍ରାନ୍ତ ହୋଇଥିବା ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଏ ।^[୧] ଆରଏସଭି ଋତୁରେ ଏହା ମାଂସପେଶୀରେ (IM) ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ମାସକୁ ଥରେ ଦିଆଯାଏ ।^[୧] ^[୫]

ସବୁଠାରୁ ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ହେଉଛି ଜ୍ୱର ଏବଂ ରାସ୍।^[୧] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲକ୍‌ସିସ୍ ଏବଂ କମ୍ ରକ୍ତ ପ୍ଲାଟେଲେଟ୍ ସ୍ତର ହୋଇପାରେ ।^[୪] ^[୬] ଏହା ବୟସ୍କ ଲୋକମାନଙ୍କଠାରେ ବ୍ୟବହୃତ ହୁଏ ନାହିଁ ।^[୪] ଏହା ଆରଏସଭିର ଫ୍ୟୁଜନ୍ ପ୍ରୋଟିନ୍ ଏ ବିରୁଦ୍ଧରେ ନିର୍ଦ୍ଦେଶିତ ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଫୁସଫୁସର କୋଷରେ ପ୍ରବେଶକୁ ଅବରୋଧ କରିଥାଏ ।^[୧]

୧୯୯୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୧୯୯୯ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ପାଲିଭିଜୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୧] କାନାଡାରେ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୭,୦୦୦ ସିଏଡି ଅଟେ ।^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୫୬୦ ପାଉଣ୍ଡ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ୧୦୦ ମିଗ୍ରା ପାଇଁ ପ୍ରାୟ ୩,୨୦୦ ଡଲାର ଥିଲା ।^[୬] ^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Synagis EPAR". European Medicines Agency (EMA). Archived from the original on 15 August 2020. Retrieved 20 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ "Synagis 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 12 August 2020. Archived from the original on 2 March 2021. Retrieved 20 August 2020.
↑ "Synagis- palivizumab injection, solution". DailyMed. 12 May 2017. Archived from the original on 7 August 2020. Retrieved 20 August 2020.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Palivizumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 12 September 2021.
↑ Borchers AT, Chang C, Gershwin ME, Gershwin LJ (December 2013). "Respiratory syncytial virus--a comprehensive review". Clinical Reviews in Allergy & Immunology. 45 (3): 331–79. doi:10.1007/s12016-013-8368-9. PMC 7090643. PMID 23575961.
↑ ^୬.୦ ^୬.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 702. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Provinces spent $43M on preemie drug experts say can be made for a fraction of the cost". CBC. Archived from the original on 3 May 2021. Retrieved 12 September 2021.
↑ "Synagis Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 20 August 2016. Retrieved 12 September 2021.

[EPAR2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Synagis EPAR". European Medicines Agency (EMA). Archived from the original on 15 August 2020. Retrieved 20 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[2] "Synagis 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 12 August 2020. Archived from the original on 2 March 2021. Retrieved 20 August 2020.

[Synagis_FDA_label-3] "Synagis- palivizumab injection, solution". DailyMed. 12 May 2017. Archived from the original on 7 August 2020. Retrieved 20 August 2020.

[AHFS2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Palivizumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 12 September 2021.

[Bor2013-5] Borchers AT, Chang C, Gershwin ME, Gershwin LJ (December 2013). "Respiratory syncytial virus--a comprehensive review". Clinical Reviews in Allergy & Immunology. 45 (3): 331–79. doi:10.1007/s12016-013-8368-9. PMC 7090643. PMID 23575961.

[BNF80-6] ୬.୦ ^୬.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 702. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[7] "Provinces spent $43M on preemie drug experts say can be made for a fraction of the cost". CBC. Archived from the original on 3 May 2021. Retrieved 12 September 2021.

[8] "Synagis Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 20 August 2016. Retrieved 12 September 2021.

[୪]

[୧]

[୫]

[୨]

[୩]

[୬]

[୭]

[୮]